Lessons from phase III clinical trials on anti-VEGF therapy for cancer (Q36366446)

13 August 2017

1 reference

title

Lessons from phase III clinical trials on anti-VEGF therapy for cancer (English)

1 reference

13 August 2017

phase III clinical trial

0 references

1

Rakesh K Jain

1 reference

13 August 2017

Dan G Duda

2

1 reference

PubMed ID

16407877

13 August 2017

Jeffrey W Clark

series ordinal

3

1 reference

PubMed ID

16407877

13 August 2017

Jay S Loeffler

series ordinal

4

1 reference

13 August 2017

1 January 2006

1 reference

Nature Clinical Practice Oncology

13 August 2017

1 reference

13 August 2017

3

1 reference

13 August 2017

1

1 reference

13 August 2017

24-40

1 reference

Transplacental carcinogenesis by stilbestrol

13 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Angiogenesis in life, disease and medicine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Multi-kinase inhibitors create buzz at ASCO.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Tumor induction of VEGF promoter activity in stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Success of bevacizumab trials raises questions for future studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Expanding the clinical development of bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

VEGF-targeted therapy: therapeutic potential and recent advances

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Cancer. Encouraging results for second-generation antiangiogenesis drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Bevacizumab--current status and future directions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Molecular regulation of vessel maturation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Repopulation of cancer cells during therapy: an important cause of treatment failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Tumor response to radiotherapy regulated by endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

ATM regulates target switching to escalating doses of radiation in the intestines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

The role of neuropilin in vascular and tumor biology.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Interstitial fluid pressure in intracranial tumours in patients and in rodents

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Lymphatic metastasis in the absence of functional intratumor lymphatics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Imaging angiogenesis: applications and potential for drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Identification of clinically useful cancer prognostic factors: what are we missing?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Circulating endothelial cells. Biomarker of vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Vascular endothelial growth factor in pleural effusions of different origin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0403

7 January 2021

Identifiers

DOI

10.1038/NCPONC0403

1 reference

13 August 2017

1 reference

PubMed ID

16407877